Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model

Immunology Letters

Volumn 113, Issue 2, 2007, Pages 90-98

  Li, Ning ^a   Qin, Hanjun ^a,c   Li, Xiaozhu ^b   Zhou, Chunxia ^a   Wang, Dongmei ^a   Ma, Wenbo ^a   Lin, Chen ^a   Zhang, Youhui ^a   Wang, Shengdian ^b   Zhang, Shuren ^a  

^a CANCER HOSPITAL   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Anti CTLA 4; PAP; Prostate cancer; PSA; PSM; Tumor cell vaccine

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; PREVENTION AND CONTROL; PRIORITY JOURNAL; PROSTATE TUMOR; SPLEEN CELL; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 35248897095     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.07.019     Document Type: Article

References (40)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics 2006. CA Cancer J Clin 56 (2006) 106-130
2. Berges R.R., Vukanovic J., Epstein J.I., CarMichel M., Cisek L., Johnson D.E., et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1 (1995) 473-480
3. Hillman G.G., Triest J.A., Cher M.L., Kocheril S.V., and Talati B.R. Prospects of immunotherapy for the treatment of prostate carcinoma: a review. Cancer Detect Prev 23 (1999) 333-342
4. Heiser A., Dahm P., Yancey D.R., Maurice, Boczkowski D., Nair S.K., et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J. Immunol 164 (2000) 5508-5514
5. Tjoa B., Boynton A., Kenny G., Ragde H., Misrock S.L., and Murphy G. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 28 (1996) 65-69
6. Wang Y., Harada M., Yano H., Ogasawara S., Takedatsu H., Arima Y., et al. Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J Immunother 28 (2005) 535-541
7. Ferrone S., Finerty J.F., Jaffee E.M., and Nabel G.J. How much longer will tumour cells fool the immune system?. Immunol. Today 21 (2000) 70-72
8. Gilboa E. The makings of a tumor rejection antigen. Immunity 11 (1999) 263-270
9. Ikeda H., Lethe B., Lehmann F., van Baren N., Baurain J.F., de Smet C., et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6 (1997) 199-208
10. Velders M.P., Weijzen S., Eiben G.L., Elmishad A.G., Kloetzel P.M., Higgins T., et al. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 166 (2001) 5366-5373
11. Qin H., Zhou C., Wang D., Ma W., Liang X., Lin C., et al. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Immunol Lett 99 (2005) 85-93
12. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90 (1997) 3245-3287
13. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
14. Ravetch J.V. Fc receptors: rubor redux. Cell 78 (1994) 553-560
15. Regnault A., Lankar D., Lacabanne V., Rodriguez A., Thery C., Rescigno M., et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189 (1999) 371-380
16. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
17. Willimann K., Legler D.F., Loetscher M., Roos R.S., Delgado M.B., Clark-Lewis I., et al. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 28 (1998) 2025-2034
18. Gunn M.D., Tangemann K., Tam C., Cyster J.G., Rosen S.D., and Williams L.T. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci USA 95 (1998) 258-263
19. Nagira M., Imai T., Yoshida R., Takagi S., Iwasaki M., Baba M., et al. A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells. Eur J Immunol 28 (1998) 1516-1523
20. Kim C.H., Pelus L.M., Appelbaum E., Johanson K., Anzai N., and Broxmeyer H.E. CCR7 ligands, SLC/6Ckine/Exodus2/TCA4 and CKβ-11/MIP-3β/ELC, are chemoattractants for CD56(+)CD16(-) NK cells and late stage lymphoid progenitors. Cell Immunol 193 (1999) 226-235
21. Qin H., Zhou C., Wang D., Liang X., Lin C., Zhang Y., et al. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens. Immunology 117 (2006) 419-430
22. Egen J.G., Kuhns M.S., and Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 3 (2002) 611-618
23. Davis S.J., Ikemizu S., Evans E.J., Fugger L., Bakker T.R., and van der Merwe P.A. The nature of molecular recognition by T cells. Nat Immunol 4 (2003) 217-224
24. Brunet J.F., Denizot F., Luciani M.F., Roux-Dosseto M., Suzan M., Mattei M.G., et al. A new member of the immunoglobulin superfamily: CTLA-4. Nature 328 (1987) 267-270
25. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1 (1994) 405-413
26. Kearney E.R., Walunas T.L., Karr R.W., Morton P.A., Loh D.Y., Bluestone J.A., et al. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J Immunol 155 (1995) 1032-1036
27. + TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein. J Immunol 166 (2001) 3900-3907
28. Dunn I.S., and Blattner F.R. Charons 36 to 40: multi enzyme, high capacity, recombination deficient replacement vectors with polylinkers and polystuffers. Nucleic Acids Res 15 (1987) 2677-2698
29. Haeffner-Cavaillon N., Klein M., and Dorrington K.J. Studies on the Fc gamma receptor of the murine macrophage-like cell line P388D1. I. The binding of homologous and heterologous immunoglobulin G1. J Immunol 123 (1979) 1905-1913
30. Horton H.M., Anderson D., Hernandez P., Barnhart K.M., Norman J.A., and Parker S.E. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci USA 96 (1999) 1553-1558
31. Gilboa E., Nair S.K., and Lyerly H.K. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 46 (1998) 82-87
32. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application and optimization. Annu Rev Immunol 18 (2000) 927-974
33. Cyster J.G. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med 189 (1999) 447-450
34. Yang S.C., Hillinger S., Riedl K., Zhang L., Zhu L., Huang M., et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 10 (2004) 2891-2901
35. Murray J.S. How the MHC selects Th1/Th2 immunity. Immunol Today 19 (1998) 157-163
36. Ohashi P.S. T cell selection and autoimmunity: flexibility and tuning. Curr Opin Immunol 8 (1996) 808-814
37. Bowne W.B., Srinivasan R., Wolchok J.D., Hawkins W.G., Blachere N.E., Dyall R., et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 190 (1999) 1717-1722
38. Houghton A.N., Gold J.S., and Blachere N.E. Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 13 (2001) 134-140
39. Kumar V., Stellrecht K., and Sercarz E. Inactivation of T cell receptor peptide-specific CD4 regulatory T cells induces chronic experimental autoimmune encephalomyelitis (EAE). J Exp Med 184 (1996) 1609-1617
40. + T cells, are required for the development of experimental autoimmune gastritis. Immunology 93 (1998) 405-408